MothaffarF.RimawiMD

Oncology • Houston, TX

Breast Cancer

Professor and Executive Medical Director, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine

Join to view full profile

Dr. Rimawi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Rimawi's full profile

Already have an account?

Office
1504 Taub Loop
Houston, TX 77030
Phone+1 713-873-8890

Fax+1 713-798-8884

Summary

Dr. Mothaffar Rimawi is an oncology specialist with a subspecialty in breast cancer, based in Houston, TX. He completed his medical education at the University of Jordan Faculty of Medicine, followed by extensive training at Baylor College of Medicine, where he also held several academic positions, including his current role as Professor and Executive Medical Director at the Dan L Duncan Comprehensive Cancer Center. Dr. Rimawi is experienced in chemotherapy, hormone therapy, monoclonal antibody tumor therapy, and clinical research, with numerous publications focusing on breast cancer treatment. He has been involved in clinical trials related to breast cancer therapies, and his accolades include being recognized as one of the Top Doctors in Southeast Texas.

Education & Training

Baylor College of MedicinePost-Doctoral Fellowship, 2003 - 2005
Baylor College of MedicineFellowship, Hematology and Medical Oncology, 2001 - 2004
Baylor College of MedicineResidency, Internal Medicine, 1998 - 2001
University of Jordan Faculty of MedicineClass of 1997

Certifications & Licensure

TX State Medical License 2005 - 2026
IN State Medical License 2004 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Top Doctors:SE Texas Castle Connolly, 2013
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

Neoadjuvant Herceptin in Patients With Breast Cancer Start of enrollment: 2001 Oct 01
Terminated
Phase 2
Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer Start of enrollment: 2003 Jan 01
Terminated
Phase 2
Neoadjuvant GW572016 to Treat Breast Cancer Start of enrollment: 2004 Aug 01
Completed
Phase 2
Nexium Study To Suppress Nausea During Chemotherapy Start of enrollment: 2005 Aug 01
Terminated
Phase 3
Extension Neoadjuvant Taxotere: Study of the Effects of Taxotere in Patients With Breast Cancer Start of enrollment: 2002 Jan 01
Terminated
Phase 2
Biologic Correlative Taxotere/AC Start of enrollment: 2002 Apr 01
Completed
Phase 2
Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients Start of enrollment: 2004 Sep 01
Completed
Phase 2
Lapatinib and Trastuzumab With or Without Endocrine Therapy Start of enrollment: 2008 May 01
Completed
Phase 2
Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer Start of enrollment: 2007 Dec 01
Completed
Phase 2
Brain Mets - Capecitabine Plus Sunitinib and WBRT Start of enrollment: 2009 Feb 01
Terminated
Phase 2
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
ACTIVE_NOT_RECRUITING
PHASE3
Efficacy Study of Dasatinib in Locally Advanced Triple-Negative Breast Cancer Patients Start of enrollment: 2008 Dec 01
Terminated
Phase 2
Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy
ACTIVE_NOT_RECRUITING
PHASE2
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
ACTIVE_NOT_RECRUITING
PHASE3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
ACTIVE_NOT_RECRUITING
PHASE3
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer Start of enrollment: 2012 Aug 01
Completed
Phase 2
Scalp Cooling to Prevent Chemo-induced Hair Loss Start of enrollment: 2014 May 15
Active, not recruiting
Not Applicable
High Dose Vitamin D vs Standard Dose Vitamin D Study Start of enrollment: 2013 Dec 01
Terminated
Phase 2
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer Start of enrollment: 2014 Jan 15
ACTIVE_NOT_RECRUITING
PHASE3
CRIZENT: Crizotinib and Sunitinib in Metastatic Breast Cancer Start of enrollment: 2014 Jun 01
Terminated
Phase 1
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer Start of enrollment: 2014 Jul 22
ACTIVE_NOT_RECRUITING
PHASE3
Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer Start of enrollment: 2015 Jun 01
Terminated
Phase 1, Phase 2
TACTIC - TAA Specific Cytotoxic T Lymphocytes in Patients With Breast Cancer Start of enrollment: 2017 Oct 10
ACTIVE_NOT_RECRUITING
PHASE2
ORIN1001 in Patients with Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer Start of enrollment: 2019 May 25
COMPLETED
PHASE1, PHASE2
Join now to see all

Publications & Presentations

PubMed

A compositeF-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026).
Maeve A Hennessy, Ashley Cimino-Mathews, Jodi M Carter, Jennifer M Kachergus, Yaohua Ma
Breast. 2025-03-01
1 citations
Patient-Derived Xenografts of Triple-Negative Breast Cancer Enable Deconvolution and Prediction of Chemotherapy Responses.
Jonathan T Lei, Lacey E Dobrolecki, Chen Huang, Ramakrishnan R Srinivasan, Suhas V Vasaikar
Biorxiv. 2025-01-08
HER2-Positive Breast Cancer Treatment and Resistance.
Jamunarani Veeraraghavan, Carmine De Angelis, Carolina Gutierrez, Fu-Tien Liao, Caroline Sabotta
Advances in Experimental Medicine and Biology. 2025-01-01

Journal Articles

The Oral Selective Oestrogen Receptor Degrader (SERD) AZD9496 Is Comparable to Fulvestrant in Antagonising ER and Circumventing Endocrine Resistance
Rinath Jeselsohn, Mothaffar F Rimawi, C Kent Osborne, Rachel Schiff, Nature

Lectures

Advances in HER2-Positive Breast Cancer
2012 International Symposium, San Antonio, Texas, USA
Advances in HER2-Positive Breast Cancer
San Antonio Breast Cancer Symposium, 2012 International Symposium, San Antonio, Texas, USA

Press Mentions

This Blood Test Screens for 50 Different Types of Cancer. Is It Worth the $949 Price Tag?January 17th, 2025
Greenwich LifeSciences Provides Year End UpdateDecember 29th, 2022
$NCI/NIH Award $2 Million to Immunicom to Initiate Clinical Trial Evaluating Breakthrough Immunopheresis® LW-02 Molecular Subtractive Therapy in Refractory ER+/Her2- Breast Cancer$
NCI/NIH Award $2 Million to Immunicom to Initiate Clinical Trial Evaluating Breakthrough Immunopheresis® LW-02 Molecular Subtractive Therapy in Refractory ER+/Her2- Breast CancerJune 14th, 2022
Join now to see all